Abstract: Embodiments of the present disclosure pertain to methods of modulating a stress response in a eukaryotic organism against an environmental stress by introducing an RNA fragment (RF) or an antisense nucleotide to the eukaryotic organism. Thereafter, the RF or antisense nucleotide modulates the stress response against the environmental stress. Additional embodiments of the present disclosure pertain to the RFs and antisense nucleotides of the present disclosure. The RFs generally include: a sequence recognition site that contains a reverse complement sequence of a nucleotide sequence of the organism; and a stem loop structure with a paired region that includes paired RNA nucleotides, and an unpaired region that includes unpaired RNA nucleotides in the form of a loop. The antisense nucleotides may include a reverse complement sequence of the RFs.

Abstract: Provided is a high-strength steel sheet having high impact resistance. The steel sheet includes: by weight %, carbon (C): 0.05% to 0.14%, silicon (Si): 0.01% to 1.0%, manganese (Mn): 1.5% to 2.5%, aluminum (Al): 0.01% to 0.1%, chromium (Cr): 0.005% to 1.0%, phosphorus (P): 0.001% to 0.05%, sulfur (S): 0.001% to 0.01%, nitrogen (N): 0.001% to 0.01%, niobium (Nb): 0.005% to 0.06%, titanium (Ti): 0.005% to 0.11%, and the balance of iron (Fe) and inevitable impurities. The steel sheet has a microstructure comprising ferrite and bainite in a total area fraction of 90% or more. The steel sheet has a value of 0.05 to 1.0 as a shear texture ({110}<112>, {112}<111>) area ratio of a center region (ranging deeper than 1/10t to ½t in a thickness direction, t refers to thickness (mm)) and a surface region (ranging from a surface to 1/10t in the thickness direction).

Abstract: A wire terminal connector is provided that includes a clamping portion that encircles a conductor exposed at an end of an electric wire in a clamping manner. The clamping portion also has a plurality of recesses that are formed on a portion thereof in contact with the conductor. In addition, the wire terminal connector includes a grip portion that encircles a sheath of the electric wire.

Abstract: An automatic slope adjusting device is provided herein. The automatic slope adjusting device may include a slope type footrest unit configured to form a sloped passage; and a driving unit configured to adjust an inclination angle of the slope type footrest unit, and a length of the slot type footrest unit in a forward-backward direction thereof.

Abstract: The present invention relates to a functional beverage composition comprising chlorella and deep sea water. The composition comprises 0.1-5 wt % of chlorella powder, 90-99 wt % of deep sea water, 0.001-0.5 wt % of a grapefruit extract, 0.01-5 wt % of honey, 0.01-5 wt of polydextrose, 0.001-1 wt % of citric acid, and 0.001-0.1 wt % of enzyme-treated stevia. Thus, the functional properties of deep sea water and chlorella, including antioxidant, anticancer, anti-inflammatory, cerebral vascular and cardiovascular disease inhibitory and anti-diabetic functions, can be provided by taking the beverage composition.

Abstract: This present invention relates to novel compounds, isomer thereof or pharmaceutically acceptable salts thereof as vanilloid receptor (Vanilloid Receptor 1; VR1; TRPV1) antagonist; and a pharmaceutical composition containing the same. The present invention provides a pharmaceutical composition for preventing or treating a disease such as pain, migraine, arthralgia, neuralgia, neuropathies, nerve injury, skin disorder, urinary bladder hypersensitiveness, irritable bowel syndrome, fecal urgency, a respiratory disorder, irritation of skin, eye or mucous membrane, stomach-duodenal ulcer, inflammatory diseases, ear disease, and heart disease.

Abstract: This present invention relates to novel compounds, isomer thereof or pharmaceutically acceptable salt thereof as vanilloid receptor (Vanilloid Receptor 1; VR1; TRRPV1) antagonist; and a pharmaceutical composition containing the same. The present invention provides a pharmaceutical composition for preventing or treating a disease such as pain, migraine, arthralgia, neuralgia, neuropathies, nerve injury, skin disorder, urinary bladder hypersensitiveness, irritable bowel syndrome, fecal urgency, a respiratory disorder, irritation of skin, eye or mucous membrane, stomach-duodenal ulcer, inflammatory diseases, ear disease, and heart disease.

Abstract: 2-cyclopenten-1-one oxime derivatives represented by Formula (I), or pharmaceutically acceptable salts thereof inhibit the production of TNF-? or PDE4, and therefore show therapeutic effect in inflammatory or immunological disorders mediated through TNF-? or PDE4.

Abstract: This present invention relates to novel compounds, isomer thereof or pharmaceutically acceptable salts thereof as vanilloid receptor (Vanilloid Receotor 1; VR1; TRPV1) antagonist; and a pharmaceutical composition containing the same. The present invention provides a pharmaceutical composition for preventing or treating a disease such as pain, migraine, arthralgia, neuralgia, neuropathies, nerve injury, skin disorder, urinary bladder hypersensitiveness, irritable bowel syndrome, fecal urgency, a respiratory disorder, irritation of skin, eye or mucous membrane, stomach-duodenal ulcer, inflammatory diseases, ear disease, and heart disease.

Abstract: Provided is a bi-directional optical module including: a transmission optical element including an SOA (semiconductor optical amplifier) aligned on an optical axis of an LD (laser diode) formed on a substrate; and a reception optical element comprising a PD (photodiode) including a light receiving surface perpendicular to the optical axis of the LD of the transmission optical element.